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Introduction of cisplatin based chemotherapy has revolutionized the treatment of germ cell tumors. A common side effect of
multiday cisplatin chemotherapy is severe nausea and vomiting. Considerable progress has been made in the control of these
side effects since the introduction of cisplatin based chemotherapy in the 1970s. Germ cell tumor which is a model for a curable
neoplasm has also turned into an excellent testing ground to develop effective strategies to prevent chemotherapy induced nausea
and vomiting (CINV) in multiday cisplatin based regimens. The use of combination of a 5-hydroxytryptamine (HT)
3
receptor
antagonist, a neurokinin-1 (NK
1
) antagonist, and dexamethasone has greatly improved our ability to prevent and control acute and
delayedCINV.Mechanism and pattern of CINVwithmultiday chemotherapymay differ from those in single day chemotherapy and
therefore efficacy of antiemetic drugs as observed in single day chemotherapymay not be applicable.There are only few randomized
clinical trials with special emphasis onmultiday chemotherapy. Further studies are essential to determine the efficacy, optimal dose,
and duration of the newer agents and combinations in multiday cisplatin based chemotherapy.
1. Introduction
Germ cell tumors are rare cancers accounting for only 1%
of all malignancies in American males. The introduction
of cisplatin based combination chemotherapy revolution-
ized the treatment of germ cell tumors. The majority of
patients with testicular cancer are cured with standard dose
cisplatin based combination chemotherapy [1]. A common
side effect of cisplatin based regimens is severe nausea and
vomiting. Cisplatin in germ cell tumors is administered for
five consecutive days and is appropriately categorized as
highly emetogenic chemotherapy (HEC) with patients being
vulnerable to nausea and vomiting on all five days. Median
number of emetic episodes with cisplatin based regimens in
the 1970s and the 1980s for germ cell tumors on day 1 was ten
and decreasing on subsequent days [2].These symptomswere
significantly debilitating for patients. Considerable progress
has been made in the control of nausea and vomiting from
those early days but there is still paucity of data on antiemetic
regimens for patients undergoing multiday cisplatin com-
bination chemotherapy regimen. Germ cell tumor, which
is a model for a curable neoplasm, has also turned into
an excellent testing ground to develop effective strategies
to prevent chemotherapy induced nausea and vomiting
(CINV) in these regimens. Phases II and III randomized
clinical trials focusing on multiday chemotherapy regimens
are summarized in Table 1. The purpose of this paper is
to review our current understanding of CINV in multiday
cisplatin regimens and to evaluate clinical agents available for
prevention and treatment of CINV as well as areas of future
research.
2. Pathophysiology
It has been established that different pathways exist in the
body that induce emesis, each relying on a set of different neu-
rotransmitters, including serotonin, dopamine, histamine,
and substance P. Receptors for these neurotransmitters are
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Table 1: Selected phases II and III trials of various agents for treatment of chemotherapy induced nausea and vomiting in patients undergoing
multiday cisplatin based chemotherapy.
Study Phase 𝑁 CINV prophylaxis Emesis Nausea
Day 1 CR Days 1–5 CR
Einhorn et al.,
1990 [14] II 36 Ondansetron 77% 30% NA
Sledge et al.,




(𝑝 < 0.001) 30% versus 9% (𝑝 = 0.002)
VAS scores 8 versus








(𝑝 < 0.001) 49% versus 35%. NA






95% versus 82% 55% versus 32% (𝑝 = 0.22) VAS scores 5.5 versus15 (p = 0.046)
Noble et al.,
1994 [18] III 200
Ondansetron versus
granisetron NA
40% versus 44% Patient









73% versus 41% (𝑝 < 0.0001).
CR rates on each study day
were also significantly higher
(𝑝 = 0.029)
VAS score of 0 (no
nausea) day 1: 88%
versus 60%




2007 [23] II 41
Palonosetron +
dexamethasone 88% 51%
No or mild nausea,
self-reported 59%
Albany et al.,
2012 [24] III 69






NA 47% versus 15% (𝑝 = 0.01)
VAS: aprepitant better
than placebo on all 6
days
Hamada et al.,




NA 90% Mild to no nausea70%
CR: complete response (no emesis and no need for rescue medication); VAS: visual analog scale for nausea; 5-HT3 RA: 5-hydroxytryptamine receptor
antagonists; NA: not available.
found in high numbers in the dorsal vagal complex, area
postrema, and gastrointestinal tract [3]. Cisplatin damages




in the GI mucosa. Released 5-HT
3
binds to its receptors
on the vagal afferent neurons and this binding activates
the chemoreceptor trigger zone (CTZ) and vomiting center
(VC). When CTZ is activated, it also releases various neuro-
transmitters which in turn stimulate the VC. Once activated,
the VC modulates efferent transmission to respiratory, vaso-
motor, and salivary centers as well as to abdominal muscles,
diaphragm, and esophagus, resulting in emesis [3, 4].
Substance P is a neurotransmitter of the tachykinin family
and is widely located in the central and peripheral nervous
system, including gut, the nucleus tractus solitarius (NTS),
and the area postrema. It acts through the neurokinin-1
(NK
1
) pathway and has been implicated in the pathogenesis
of emesis [5]. Preclinical studies have shown that NK
1
-
receptor antagonists prevent emesis by acting centrally within
the NTS [6]. Evaluation of NK
1
receptor antagonists in
animal emesis models also indicated that they were highly
effective against the delayed phase of emesis caused by cis-
platin [5, 6]. Dopamine receptors are also present in CTZ and
dopamine antagonists like phenothiazines, butyrophenones,
and metoclopramide have been effective in treating CINV,
although restricted by their side effects.
3. Historical Perspective
Phenothiazines, introduced as antipsychotic medications,
were the first group of drugs to demonstrate activity in
chemotherapy induced vomiting and remained the main-
stay of antiemetic therapy for almost 3 decades from their
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introduction in the 1950s. Standard agents included chlorpro-
mazine hydrochloride and prochlorperazine which mainly
acted as dopamine antagonists. Low doses were not effective
while higher doses carried risk of extrapyramidal reactions,
liver dysfunction, marrow aplasia, and excessive sedation.
They were also ineffective if patient failed to respond to it in
the first course of treatment [7].
Metoclopramide, a substituted benzamide, was used in
Europe for decades for prevention ofmotion sickness but was
considered ineffective against chemotherapy induced nausea.
But in the 1980s, it was discovered that massive doses of the
drug (2mg/kg given before and after chemotherapy) helped
to minimize nausea and vomiting in most patients treated
with cisplatin. However, high doses of metoclopramide were
associated with troublesome Parkinsonian symptoms which
were somewhat dissipated with addition of diphenhydramine
[8].
Steroids, particularly dexamethasone, were tried alone
and in various combinations with older agents with good
control of nausea and vomiting. In combination with meto-
clopramide and other agents like lorazepam, it was noted
that 50–60% of patients experienced no emesis compared
to around 20% with either of the agents alone [9]. CINV
prophylaxis with combination of dexamethasone and meto-
clopramide was the mainstay of treatment in the 1980s till
introduction of ondansetron. At IndianaUniversity, metoclo-
pramide or lorazepam in combination with dexamethasone
before and after cisplatin for the first 2 days, followed
by chlorpromazine on the other 3 days, was utilized with
adequate antiemetic efficacy in patients undergoing multiday
cisplatin based chemotherapy.
Based on observations that smoking marijuana helps
to alleviate CINV, tetrahydrocannabinol as an antiemetic
agent was evaluated by Sallan et al. Antiemetic effect was
observed in 14 of 20 tetrahydrocannabinol courses and in
0 of 22 placebo courses. No patient had vomiting episodes
while experiencing a subjective “high” [10]. Subsequently, in
a double-blind prospective study, Einhorn et al. demon-
strated superiority of nabilone, a synthetic cannabinoid, com-
pared to prochlorperazine in patients undergoing multiday
cisplatin chemotherapy. In patients treated with prochlor-
perazine, the mean number of emetic episodes on the first
day of multiple-day cisplatin therapy was 10.3 compared with
7.05 on nabilone. It was however associated with significant
dry mouth and dysphoria [11]. This has not been replicated
in the era of 5-HT
3
receptor antagonists. A study by Meiri
et al. evaluating dronabinol, ondansetron, or combination
demonstrated equivalent efficacy between all groups and did




4. 5-HT3 Receptor Antagonist
Just as cisplatin revolutionized the cure rate for germ cell
tumors, ondansetron, the first 5-HT
3
receptor antagonist,
greatly mitigated the severe cisplatin-associated nausea and
vomiting [13]. In 1990, Einhorn et al. piloted ondansetron
0.15mg/kg intravenously for 3 doses in a phase II study with
35 patients receiving 4- to 5-day cisplatin based regimens.
Ten patients (29%) had no vomiting or retching throughout
the entire study period and 18 patients (51%) experienced
two or fewer emetic episodes during the entire study period.
Ondansetron was very well tolerated in all 35 patients [14]. A
subsequent phase III study by Sledge Jr. et al. [15] evaluated 3
intravenous doses of ondansetron 0.15mg/kg intravenously
or metoclopramide 1mg/kg in patients undergoing multi-
day cisplatin chemotherapy. Proportion of patients with no
emetic episodes throughout the entire study period was
higher in the ondansetron arm (30% versus 9%, 𝑝 = 0.077).
Significantly fewer antiemetic treatment failures (more than
five emetic episodes or withdrawal from the study) occurred
with patients given ondansetron (9%) than with those
given metoclopramide (50%) during the entire study period
(𝑝 = 0.002). Although ondansetron clearly demonstrated
superiority over metoclopramide as a single agent, 70% of
patients treated with ondansetron in this study experienced
at least one emetic episode during the 5-day treatment
period. Ondansetron was very efficacious on the first day




receptor antagonists, such as granisetron
and dolasetron, were subsequently approved by the FDA and
have demonstrated equivalent efficacy and toxicity relative
to ondansetron [16]. A single blind prospective study by
the granisetron study group evaluated efficacy of prophylac-
tic intravenous granisetron versus alizapride (a substituted
benzamide) with dexamethasone in patients receiving frac-
tionated chemotherapy (cisplatin or ifosfamide) for 5 days.
Granisetron was superior to the combination in preventing
nausea and vomiting, 54% versus 43% complete responders,
respectively, in the cisplatin group. Adverse events were
also lower in the granisetron group [17]. A subsequent,
double-blind, randomized, and crossover comparison of
single daily intravenous doses of granisetron compared with
three daily intravenous doses of ondansetron in 5-day frac-
tionated chemotherapy demonstrated equal efficacy, safety,
and patient preference, with both agents achieving good
control of emetic symptoms with 5-day complete response




receptor antagonists were ineffective
in prevention of delayed CINV, which is a major issue with
multiday cisplatin based chemotherapy. A meta-analysis of 5
studies comparing a 5-HT
3
receptor antagonist as monother-
apy compared to placebo showed no clinical evidence of
improvement of control of delayed emesis with addition
of 5-HT
3
receptor antagonists [19]. In early clinical trials,
addition of dexamethasone consistently improved efficacy
compared to 5-HT
3
receptor antagonist alone, making it
the standard for patients receiving cisplatin based therapy.
In a multicenter trial looking at ondansetron plus dexam-
ethasone compared to ondansetron alone in cisplatin based
chemotherapy, patients who received the combination had
higher complete antiemetic response rate (61% versus 46%)
and less nausea as per visual analog scale (18% versus 33%)
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Table 2: Antiemetic prophylaxis regimen for multiday cisplatin chemotherapy for germ cell tumors, Indiana University protocol.

















∗Alternatively, ondansetron 16mg orally daily can be utilized from days 1–5 if palonosetron is not available.
[20]. Fox et al. conducted a phase III trial in 44 patients
comparing ondansetron with combination of ondansetron,
dexamethasone, and chlorpromazine in multiday cisplatin
chemotherapy. There was a reduction in total number of
emetic episodes in favor of the combination arm but this did
not reach statistical significance (55 versus 32%, 𝑝 value =
0.22).Mean change of nausea controlmeasured by visual ana-
log scale (VAS) was superior with the combination regimen.
It is unsure what role chlorpromazine played in this study and
it is questionable that it addedmuch value to the ondansetron
and dexamethasone combination [21]. A bigger phase III
trial demonstrated that adding dexamethasone to dolasetron
significantly increased effectiveness in preventing nausea
and vomiting related to fractionated cisplatin chemotherapy.
Complete response rates were significantly better in all 5 days
in the combination arm compared to dolasetron alone [22].
These studies clearly established the superiority of 5-HT
3
receptor antagonist-dexamethasone combination inmultiday
cisplatin based chemotherapy and soon became the standard
of care.
However optimal duration of dexamethasone has never
been clearly established. Side effects of 5 consecutive days
of dexamethasone during cisplatin administration and three
additional days for delayed nausea and vomiting and repeated
courses every 3 weeks are going to be substantial [26]. In
a retrospective study evaluating dexamethasone toxicity in
patients receiving moderately emetogenic chemotherapy, all
patients received dexamethasone (10 or 20mg intravenously)
and oral dexamethasone for delayed prophylaxis (4mg twice
daily for 2-3 days). In this study, 45% of patients reported
moderate to severe problems with insomnia, 27% had indi-
gestion or epigastric discomfort, and 27% had agitation [27].
Late toxicity from dexamethasone is of particular concern,
particularly with avascular necrosis of the hip on long term
dexamethasone [26, 28]. Our antiemetic prophylaxis regimen
for cisplatin chemotherapy in germ cell tumors restricts
dexamethasone to days 1 and 2 of cisplatin administration
(Table 2).
Palonosetron is a unique 5-HT
3
receptor antagonist with
activity at both central and GI sites and also has a long
plasma terminal phase elimination half-life of approximately
40 hours [29]. A phase II trial by Einhorn et al. [23] evaluated
palonosetron 0.25mg IV on chemotherapy days 1, 3, and 5
plus dexamethasone in patients receiving multiday cisplatin
chemotherapy for germ cell tumor. Majority of patients had
no emesis at any time throughout days 1–5 (51%) or days
6–9 (83%), had no moderate or severe nausea, and did
not require rescue medication. Most patients reported that
the nausea they experienced had no significant effect on daily
functioning. Recently, two studies have demonstrated that
single dose (0.25mg IV) of palonosetron maintains response
rates for acute and delayed CINV over repeated courses
of chemotherapy in patients on HEC [30, 31]. An open-
label, single-arm, and multicenter study was performed in
patients with testicular germ cell tumor who were scheduled
to receive 5-day cisplatin based combination chemotherapy.
The antiemetic therapy consisted of palonosetron 0.75mg on
day 1, aprepitant 125mg on day 1, 80mg on days 2 to 5, dexam-
ethasone 9.9mg on day 1, and 6.6mg on days 2 to 8. Complete
response (CR) rate, which was defined as no vomiting and no
rescue medication use, was achieved in 90% of the patients in
the first chemotherapy course, and high CR rates were also
observed in the second and third courses (82.1 and 78.3%,
resp.) [25]. This trial was conducted in Japan, where 0.75mg
intravenous dose of palonosetron is the commonly used
dose. Trials evaluating single dose (0.25mg intravenously) of
palonosetron or head to head comparison of palonosetron
compared to ondansetron in multiday cisplatin chemother-
apy have not been performed. Our antiemetic prophylaxis
recommends palonosetron 0.25mg IV on days 1, 3, and 5,
based on the phase II trial results. Ondansetron 16mg orally
daily on days 1–5 can be alternatively used in patients who are
unable to get palonosetron due to insurance reasons or other
issues (Table 2).
5. NK1 Receptor Antagonists
Introduction of NK
1
receptor antagonists substantially inc-
reased our ability to control nausea and vomiting and is
now an important component of antiemetic management
strategies in multiday cisplatin based chemotherapy. In
the first multicenter, double-blind, and placebo-controlled
trial conducted by Navari et al., addition of NK
1
receptor
antagonists (aprepitant) to granisetron and dexamethasone
resulted in significant decrease in acute CINV and delayed
emesis for single day HEC [32]. In 3 studies comparing the
addition of aprepitant (125mg on day 1, 80mg on days 2
and 3) to intravenous ondansetron 32mg (on day 1) and oral
dexamethasone (12 or 20mg on days 1 and 8 or 16mg on days
2 and 3), addition of aprepitant resulted in absolute increase in
complete response rate from 11% to 20%, favoring aprepitant.
Also there was a significant benefit observed in prevention of
delayed emesis [33–35].
Albany et al. (see Table 1) conducted the first randomized,
double-blind, placebo-controlled, and phase III crossover
study evaluating the oral NK
1
antagonist aprepitant in com-
bination with several 5-HT
3
receptor antagonists (except
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palonosetron) and dexamethasone in patients with germ cell
tumors receiving 5-day cisplatin combination chemotherapy
[24]. Patients were randomly assigned to aprepitant 125mg
on day 3 and 80mg per day on days 4 through 7 or to placebo
with initial course and crossover to opposite treatment with
the second course. Among 69 patients in the study, 42%
achieved complete response for days 1–8, defined as no emetic
episodes with no use of rescue medication with aprepitant,
compared with 13% in the placebo group (𝑝 value < 0.01).
Only 16.2% of patients who got aprepitant had one or
more emetic episodes compared to 47.1% with placebo. No
statistically significant difference was noted in visual analog
scale (VAS) for nausea, but it was numerically superior with
aprepitant. Also patient preference was higher for aprepitant
cycle compared to placebo. Dexamethasone was used only
on days 1 and 2 for the acute phase to decrease the adverse
effects of corticosteroids. This may have contributed to the
loss of control on days 3 through 5 during the acute phase
and on days 6 through 8 in the delayed phase. Utilizing
dexamethasone in patients receiving three to four cycles
of BEP chemotherapy would put them at higher risk for
multiple complications including insomnia, hyperglycemia,
and avascular necrosis of hip. Palonosetron, with its longer
half-life, is probably more attractive in this setting and is
included in our antiemetic prophylaxis regimen (Table 2).
Pharmacokinetics interactions of aprepitant should be
carefully evaluated in clinical practice. It has been noted
to decrease plasma concentrations of other agents that are
metabolized by CYP3A4 or CYP2C9 [36]. Aprepitant has
been shown to cause a twofold increase in the area under the
plasma concentration curve (AUC) of dexamethasone, which
is a sensitive substrate of CYP3A4 and therefore oral steroid
dose should be reduced by 50% when used in combination
with aprepitant.Theremight also be interactionwithwarfarin
and it would require close monitoring [37].
Fosaprepitant is a water-soluble phosphoryl prodrug for
aprepitant which is administered intravenously and rapidly
converts to aprepitant within 30 minutes of administration
[38]. Single dose fosaprepitant (150mg intravenously) in
combination with granisetron 40 𝜇g/kg intravenously on day
1 and dexamethasone on days 1–3 was evaluated in a phase
II trial against control regimen of placebo plus intravenous
granisetron and dexamethasone. Complete response (no
emesis and no rescue therapy) was significantly higher in
the fosaprepitant group than in control group (64% versus
47%, resp.). The fosaprepitant regimen was more effective
than the control regimen in both the acute phase (94% versus
81%, 𝑝 = 0.0006) and the delayed phase (65% versus 49%,
𝑝 = 0.0025) [39]. Currently, the Hoosier Clinical Research
Network (HCRN) is conducting a multicenter, phase II
study of fosaprepitant with 5-HT
3
receptor antagonists and
dexamethasone in patients with germ cell tumors undergoing
5-day cisplatin based chemotherapy.
6. Novel Agents and Emerging Therapies
Netupitant and palonosetron (NEPA) is the first antiemetic
combination agent developed, comprised of a new, highly
selective NK
1
receptor antagonist, netupitant, and the 5-HT
3
receptor antagonist, palonosetron. Hesketh et al. conducted
a phase II randomized double-blind study in 694 patients
undergoing cisplatin based chemotherapy with combination
of NEPA. Different oral doses of netupitant (100, 200, and
300mg) and palonosetron 0.50mg, all given on day 1,
were compared to a standard 3-day regimen of aprepitant,
with ondansetron as an additional exploratory arm. All
NEPA doses showed superior overall complete response
rates compared with palonosetron (87.4%, 87.6%, and 89.6%
for NEPA100, NEPA200, and NEPA300, resp., versus 76.5%
palonosetron; 𝑝 value < 0.050) with the highest NEPA300
dose studied showing an incremental benefit over lower
NEPA doses for all efficacy endpoints. NEPA showed superi-
ority for all key efficacy end points of no emesis, no significant
nausea, and complete protection (no emesis and no signifi-
cant nausea) rates even during the delayed (25–120 h) phase.
Safety profile was similar to aprepitant and ondansetron
[40].This trial specifically excluded patients getting multiday
cisplatin chemotherapy but appears to be a promising therapy
warranting further evaluation with randomized clinical trials
in multiday cisplatin chemotherapy.
Olanzapine is an atypical antipsychoticmedication which
blocks multiple neurotransmitter receptors including dopa-
minergic, serotonergic, adrenergic, and histamine receptors.
Two phase III clinical trials have been conducted to evaluate
efficacy and safety of olanzapine compared with 5-HT
3
receptor antagonists. In a study by Tan et al., 229 patients
receiving moderately emetogenic chemotherapy (MEC) and
highly emetogenic chemotherapy (HEC) were randomly
assigned to azasetron, dexamethasone, and olanzapine or to
azasetron and dexamethasone. Complete response rate in
HEC group was significantly improved for both the delayed
period (69.64% versus 30.43%, 𝑝 < 0.05) and the overall
period (69.64% versus 28.26%, 𝑝 < 0.05), but no differ-
ence was noted in the acute phase. Patients reported better
quality of life on olanzapine [41]. Navari et al. conducted
an additional phase III study in patients receiving HEC. 249
patients were randomized to either olanzapine or aprepitant
in combination with palonosetron and dexamethasone. Rate
of control of chemotherapy induced emesis was comparable
between the two regimens while nausea was significantly bet-
ter controlled with olanzapine arm particularly in the delayed
phase [42]. Both these studies did include cisplatin based
chemotherapy but excluded multiday cisplatin chemother-
apy. So it is difficult to draw any conclusions about the
effectiveness of olanzapine in patients undergoing multiday
cisplatin chemotherapy without further trials. Other newer
agents like rolapitant and gabapentin have also not yet been
studied in multiday chemotherapy setting.
7. Practice Guidelines and Our Practice
Practice guidelines (from the National Comprehensive Can-
cer Network (NCCN), Multinational Association of Support-
ive Care in Cancer/European Society for Medical Oncol-
ogy (MASCC/ESMO), and American Society of Clinical
Oncology (ASCO)) recommend a combination of antiemetic
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agents for the prevention of CINV with HEC, specifically
“triple therapy” with an NK
1
receptor agonist, a 5-HT
3
receptor agonist, and dexamethasone [43–45], to be given
prophylactically on all days of chemotherapy regimen.
At Indiana University, our protocol for antiemetic pro-
phylaxis for multiday cisplatin combination chemotherapy
utilizes all three classes of recommended treatments and is







tant, and dexamethasone have substantially improved our
ability to prevent and control acute and delayed nausea
and vomiting in multiday cisplatin based chemotherapy. In
spite of significant progress made, the challenge remains in
achieving complete control as any deviation in chemotherapy
treatment course or schedule due to CINV in this curable
cancer is unacceptable. Mechanism and pattern of CINV
withmultiday chemotherapy and efficacy of antiemetic drugs
may differ from those observed in single day chemotherapy.
Newer prophylaxis regimens with fosaprepitant, NEPA, and
olanzapine have demonstrated excellent results with control
of acute and delayed nausea and vomiting in HEC, but these
have not been validated in multiday regimens yet. Rigorous
examination of newer agents with randomized clinical trials
with special emphasis on multiday chemotherapy is essential
to determine the efficacy, optimal dose, and duration of these
agents and combinations.
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